BR112017002675A2 - métodos para aperfeiçoar desempenho miocárdico em pacientes de fontan com o uso de composições de udenafila - Google Patents

métodos para aperfeiçoar desempenho miocárdico em pacientes de fontan com o uso de composições de udenafila

Info

Publication number
BR112017002675A2
BR112017002675A2 BR112017002675A BR112017002675A BR112017002675A2 BR 112017002675 A2 BR112017002675 A2 BR 112017002675A2 BR 112017002675 A BR112017002675 A BR 112017002675A BR 112017002675 A BR112017002675 A BR 112017002675A BR 112017002675 A2 BR112017002675 A2 BR 112017002675A2
Authority
BR
Brazil
Prior art keywords
methods
myocardial performance
improving myocardial
udenafil
fontan patients
Prior art date
Application number
BR112017002675A
Other languages
English (en)
Inventor
L Yeager James
Original Assignee
Mezzion Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mezzion Pharma Co Ltd filed Critical Mezzion Pharma Co Ltd
Publication of BR112017002675A2 publication Critical patent/BR112017002675A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

a presente invenção se refere, em geral, ao campo de uso de udenafila ou de um sal farmaceuticamente aceitável da mesma em pacientes que foram submetidos à operação de fontan.
BR112017002675A 2014-08-12 2015-06-30 métodos para aperfeiçoar desempenho miocárdico em pacientes de fontan com o uso de composições de udenafila BR112017002675A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462036506P 2014-08-12 2014-08-12
US201562186132P 2015-06-29 2015-06-29
PCT/US2015/038638 WO2016025100A2 (en) 2014-08-12 2015-06-30 Methods of improving myocardial performance in fontan patients using udenafil compositions

Publications (1)

Publication Number Publication Date
BR112017002675A2 true BR112017002675A2 (pt) 2017-12-12

Family

ID=55301323

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017002675A BR112017002675A2 (pt) 2014-08-12 2015-06-30 métodos para aperfeiçoar desempenho miocárdico em pacientes de fontan com o uso de composições de udenafila

Country Status (24)

Country Link
US (6) US10137128B2 (pt)
EP (2) EP4342531A2 (pt)
JP (4) JP2017524705A (pt)
KR (3) KR20170066334A (pt)
CN (1) CN107073001A (pt)
AU (3) AU2015302271B2 (pt)
BR (1) BR112017002675A2 (pt)
CA (5) CA3128691A1 (pt)
CL (1) CL2017000329A1 (pt)
CO (1) CO2017000271A2 (pt)
DO (1) DOP2017000014A (pt)
EA (1) EA201692518A3 (pt)
EC (1) ECSP17015154A (pt)
IL (2) IL285193B2 (pt)
MX (1) MX2017001396A (pt)
MY (1) MY200278A (pt)
NZ (2) NZ765796A (pt)
PE (1) PE20170469A1 (pt)
PH (1) PH12017500120A1 (pt)
SG (2) SG11201700060WA (pt)
TN (1) TN2017000029A1 (pt)
TW (5) TWI730944B (pt)
UA (1) UA120514C2 (pt)
WO (1) WO2016025100A2 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10137128B2 (en) 2014-08-12 2018-11-27 Mezzion Pharma Co., Ltd. Methods of improving myocardial performance in fontan patients using udenafil compositions
US20170112858A1 (en) * 2015-10-27 2017-04-27 New Haven Pharmaceuticals, Inc. Extended Release Aspirin
KR102249155B1 (ko) 2019-07-26 2021-05-07 주식회사 코아팜바이오 유데나필을 함유하는 약제학적 조성물
CA3155861A1 (en) * 2019-09-24 2021-04-01 Mezzion Pharma Co., Ltd. Methods of improving exercise performance, single ventricular performance, and myocardial performance index (mpi) in single ventricle heart disease, using udenafil compositions
WO2023018972A1 (en) 2021-08-13 2023-02-16 Mezzion Pharma Co., Ltd. Methods and compositions for treating fibrotic liver conditions, using udenafil compositions
WO2023121689A1 (en) 2021-12-20 2023-06-29 Mezzion Pharma Co., Ltd. Methods and compositions for improving exercise performance

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100353014B1 (ko) 1998-11-11 2002-09-18 동아제약 주식회사 발기부전 치료에 효과를 갖는 피라졸로피리미디논 화합물
US20050272741A1 (en) * 2004-01-16 2005-12-08 Jack Rychik Novel methods of treatment for Fontan patients with protein losing enteropathy
US20090186896A1 (en) 2005-09-29 2009-07-23 Bayer Healthcare Ag PDE Inhibitors and Combinations Thereof for the Treatment of Urological Disorders
NL2000291C2 (nl) 2005-11-10 2009-02-17 Pfizer Prod Inc 1-(1-(2-ethoxyethyl)-3-ethyl-7-(4-methylpyridin-2-ylamino)-1H- pyrazool(4,3-d)pyrimidine-5-yl)piperidine-4-carbonzuur en zouten daarvan.
KR100792126B1 (ko) 2006-04-04 2008-01-04 동아제약주식회사 피라졸로피리미디논 화합물을 유효성분으로 함유하는전립선 비대증 예방 및 치료제
KR101002490B1 (ko) 2007-06-09 2010-12-17 동아제약주식회사 유데나필을 유효성분으로 함유하는 만성 심부전증 치료용약학적 조성물
WO2008151734A1 (en) 2007-06-13 2008-12-18 Bayer Schering Pharma Aktiengesellschaft Pde inhibitors for the treatment of hearing impairment
KR101004205B1 (ko) 2008-12-17 2010-12-24 동아제약주식회사 유데나필 함유 서방성 제제를 제조하기 위한 제어방출 조성물
KR101071877B1 (ko) * 2009-02-18 2011-10-10 동아제약주식회사 유데나필 산부가염, 그의 제조방법 및 이를 포함하는 약학적 조성물
JP5960061B2 (ja) 2009-12-18 2016-08-02 エクソドス ライフ サイエンシーズ リミテッド パートナーシップ 末梢血管疾患を治療するための方法および組成物
WO2011126250A2 (ko) 2010-04-05 2011-10-13 에스케이케미칼 주식회사 Pde5 억제제를 함유하는 피부 주름 개선용 조성물
JP5883687B2 (ja) 2011-03-09 2016-03-15 第一三共ヘルスケア株式会社 Ｐｄｅ５阻害剤含有医薬組成物
KR101383430B1 (ko) 2012-01-26 2014-04-08 광동제약 주식회사 새로운 조합의 구강내 속붕해 필름형성 조성물 및 ｐｄｅ５ 저해제가 함유된 구강내 속붕해 필름제제
MX2015006023A (es) 2012-11-13 2016-03-31 Nusirt Sciences Inc Composiciones y metodos para incrementar el metabolismo energetico.
US10137128B2 (en) 2014-08-12 2018-11-27 Mezzion Pharma Co., Ltd. Methods of improving myocardial performance in fontan patients using udenafil compositions

Also Published As

Publication number Publication date
NZ765800A (en) 2024-03-22
JP2019077726A (ja) 2019-05-23
EP3180008A4 (en) 2018-01-24
US20180169103A1 (en) 2018-06-21
ECSP17015154A (es) 2017-05-31
TW202224685A (zh) 2022-07-01
EP3180008B1 (en) 2023-11-29
TW202002982A (zh) 2020-01-16
CA3128691A1 (en) 2016-02-18
CA2954183C (en) 2023-10-31
AU2019203706A1 (en) 2019-06-20
TN2017000029A1 (en) 2018-07-04
TWI767153B (zh) 2022-06-11
KR20170066334A (ko) 2017-06-14
CA2954183A1 (en) 2016-02-18
EA201692518A2 (ru) 2017-07-31
EP3180008A2 (en) 2017-06-21
US20160045510A1 (en) 2016-02-18
US10653698B2 (en) 2020-05-19
AU2015302271B2 (en) 2019-02-28
JP2024020187A (ja) 2024-02-14
IL285193A (en) 2021-08-31
MX2017001396A (es) 2017-12-04
IL285193B1 (en) 2023-07-01
US20190030037A1 (en) 2019-01-31
TW202118491A (zh) 2021-05-16
WO2016025100A2 (en) 2016-02-18
JP2021091721A (ja) 2021-06-17
SG11201700060WA (en) 2017-02-27
US10137128B2 (en) 2018-11-27
US20230095034A1 (en) 2023-03-30
US20220047601A1 (en) 2022-02-17
IL250547A0 (en) 2017-03-30
CA3128680A1 (en) 2016-02-18
NZ765796A (en) 2024-02-23
CA3128705A1 (en) 2016-02-18
KR20210038708A (ko) 2021-04-07
MY200278A (en) 2023-12-18
TW201617080A (zh) 2016-05-16
US20190030038A1 (en) 2019-01-31
PE20170469A1 (es) 2017-04-21
EA201692518A3 (ru) 2017-11-30
IL285193B2 (en) 2023-11-01
UA120514C2 (uk) 2019-12-26
AU2021202212A1 (en) 2021-05-06
CO2017000271A2 (es) 2017-05-31
TWI730944B (zh) 2021-06-21
CN107073001A (zh) 2017-08-18
PH12017500120A1 (en) 2017-05-29
EP4342531A2 (en) 2024-03-27
CA3128697A1 (en) 2016-02-18
AU2015302271A1 (en) 2017-01-12
CL2017000329A1 (es) 2017-11-03
DOP2017000014A (es) 2017-06-30
IL250547B (en) 2021-07-29
JP2017524705A (ja) 2017-08-31
TW202400176A (zh) 2024-01-01
KR20230116098A (ko) 2023-08-03
SG10202100300RA (en) 2021-02-25

Similar Documents

Publication Publication Date Title
DOP2020000102A (es) Compuestos útiles para inhibir a cdk7
CO2017004525A2 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
BR112018070859A2 (pt) degradantes da proteína de bet
UY36452A (es) Novedosos compuestos moduladores de fxr (nr1h4)
DOP2017000109A (es) Derivados de feniltriazol sustituido con hidroxialquilo y sus usos
UY37036A (es) Compuestos inhibidores de la quinasa de unión a tank
UY36445A (es) Compuestos moduladores de fxr (nr1h4 que contiene grupos hidroxi)
BR112017002675A2 (pt) métodos para aperfeiçoar desempenho miocárdico em pacientes de fontan com o uso de composições de udenafila
BR112017009497A2 (pt) polinucleotídeos de aadc para o tratamento da doença de parkinson
BR112017004141B8 (pt) Agente de imagemamento e seu uso
BR112016015365A8 (pt) composto, composição farmacêutica e uso de um composto
CL2016001587A1 (es) Derivado basado en 1,2-naftoquinona y método de preparación del mismo.
BR112017008799A2 (pt) composições de apilimod e métodos de uso das mesmas no tratamento de câncer renal
BR112016028845A2 (pt) composto, composição farmacêutica e uso de um composto
BR112015017241A8 (pt) composto, composição farmacêutica, uso do composto e da composição farmacêutica e kit
CL2017000715A1 (es) Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo
BR112015032526A2 (pt) composições anticaspa e métodos de uso das mesmas
BR112018012313A2 (pt) composições que compreendem 15-hepe e métodos para uso das mesmas
BR112017004136A2 (pt) sondas para imageamento de proteína de huntingtina
BR112017004140A2 (pt) sondas para imageamento de proteína de huntingtina
BR112017004134A2 (pt) ?sondas para imageamento de proteína de huntingtina?
BR112017002852A2 (pt) compostos de azetidiniloxifenilpirrolidina
CR20150653A (es) Compuestos nuevos para el tratamiento del cáncer
BR112016017620A2 (pt) Composto esteroidal para uso no tratamento da encefalopatia hepática
UY36117A (es) Composiciones farmacéuticas para el tratamiento de enfermedades infecciosas.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]